Correspondence 0001213900-24-039526 from Virpax Pharmaceuticals, Inc. (VRPX) (CIK 0001708331)
Virpax Pharmaceuticals, Inc. (VRPX) (CIK 0001708331)
Date: May 3, 2024 · CIK: 0001708331 · Accession: 0001213900-24-039526
AI Filing Summary & Sentiment
File numbers found in text: 333-278796
Letter
VIA EDGAR United States Securities Division of Corporation Finance Attention: Daniel Crawford Re: Virpax Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed April 18, 2024 File No: 333-278796
Dear Mr. Crawford:
Reference is made to our letter, filed as correspondence via EDGAR on May 2, 2024, in which we requested the acceleration of the effective date of the above-referenced Registration Statement for Thursday, May 2, 2024, at 5:00 p.m. Eastern Time.
We are no longer requesting that such Registration Statement be declared effective at this time, and we hereby formally withdraw our request for acceleration of the above referenced effective date.
Very truly yours,
VIRPAX PHARMACEUITCALS, INC.
Show Raw Text
CORRESP
1
filename1.htm
May 3, 2024
VIA EDGAR
United States Securities
and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Daniel Crawford
Re:
Virpax Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed April 18, 2024
File No: 333-278796
Dear Mr. Crawford:
Reference is made to our letter,
filed as correspondence via EDGAR on May 2, 2024, in which we requested the acceleration of the effective date of the above-referenced
Registration Statement for Thursday, May 2, 2024, at 5:00 p.m. Eastern Time.
We are no longer requesting
that such Registration Statement be declared effective at this time, and we hereby formally withdraw our request for acceleration of the
above referenced effective date.
Very truly yours,
VIRPAX PHARMACEUITCALS, INC.
By:
/s/ Gerald Bruce
Name:
Gerald Bruce
Title:
Chief Executive Officer
cc: Leslie Marlow, Blank Rome LLP
Melissa Palat Murawsky, Blank Rome LLP